Celldex also has supportive data In frontline GBM from a previously conducted phase II study known as ACT III. In that study, the median overall survival for Rintega-treated patients was 21.5 months, which exceeds the overall survival of 16 months typically seen in newly diagnosed EGFRvIII-positive GBM patients treated with surgery and chemo-radiation alone.=strong buy.
8.50 tomorrow .coming up. strong buy
Let’s take a quick look at the hedge fund sentiment on the stock, which actually proves the point made above. The number of hedge funds tracked by Insider Monkey with positions in Vipshop Holdings Ltd – ADR (NYSE:VIPS) declined to 40 from 54 during the third quarter, while the value of their investments shrank to $1.43 billion from $2.19 billion. These top money managers accumulated 14.70% of the company’s shares on September 30. George Soros’ Soros Fund Management upped its position in Vipshop Holdings Ltd – ADR (NYSE:VIPS) by 1.13 million ADSs during the September quarter, ending the three-month period with 5.88 million ADSs.= sell
Reports Q3 (Sep) earnings of RMB 1.00 per share, RMB 0.79 better than the Capital IQ Consensus of RMB 0.21; revenues rose 110.7% year/year to RMB 1.01 bln vs the RMB 1 bln Capital IQ Consensus.
Co issues in-line guidance for Q4, sees Q4 revs of 1.11-1.16 bln vs. RMB 1.15 bln Capital IQ Consensus Estimate.
The co also announced the appointment of Mr. Zhaohui Li as a director of the Company and the resignation of Mr. Zhijian Peng as a director, effective immediately. Li currently serves as Managing Partner of Tencent Investment and General Manager of Tencent Mergers & Acquisitions.strong buy.
6/1/2015 JPMorgan Chase & Co. Set Price Target Overweight $30.00 - $40.00 and8/19/2015 Summit Research Reiterated Rating Buy $38.00.strong buy.
Tower Semiconductor jumped 85 cents, or 5.9%, to $15.25 on 1.9 million shares Wednesday after beating earnings estimates. The move took it across declining topsline and lateral resistance. Look for a test up around the May and June double-top in the $17 zone, which is the first target. Beyond that, it may take a run at the March highs around $18.50.
Cody Acree from Drexel Hamilton noted that one of the most encouraging points from the press release, was Tower’s announcement that now three strategic customers have paid a total thus far of $45 million to reserve production capacity for 2016 and beyond. Results are showing strength in its RF business, broad organic growth, and the beginnings of a strong ramp of TPSCo activity, which bodes well for 2016 and 2017.
Reiterate Buy rating and $28 target price.